These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12823340)

  • 1. The pathophysiology of variant Creutzfeldt-Jacob disease: the hypotheses behind concerns for blood components and products.
    Burthem J; Roberts DJ
    Br J Haematol; 2003 Jul; 122(1):3-9. PubMed ID: 12823340
    [No Abstract]   [Full Text] [Related]  

  • 2. Creutzfeldt-Jakob disease.
    Clement P
    Haemophilia; 2000 Jul; 6 Suppl 1():68-78. PubMed ID: 10982271
    [No Abstract]   [Full Text] [Related]  

  • 3. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components.
    Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
    Vox Sang; 2006 Nov; 91(4):348. PubMed ID: 17105612
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update.
    Lescoutra-Etchegaray N; Jaffré N; Sumian C; Durand V; Correia E; Mikol J; Luccantoni-Freire S; Culeux A; Deslys JP; Comoy EE
    Transfusion; 2015 Jun; 55(6):1231-41. PubMed ID: 25647476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T; Padilla A
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The risk of prion contamination through the transfusion of cellular products].
    Lefrère JJ
    Transfus Clin Biol; 2007 May; 14(1):25-34. PubMed ID: 17499536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 10. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 11. [Aspects of the risks associated with vCJK from plasma derivatives from human plasma].
    Burger R; Offergeld R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):648-9. PubMed ID: 19557456
    [No Abstract]   [Full Text] [Related]  

  • 12. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.
    Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617
    [No Abstract]   [Full Text] [Related]  

  • 13. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 14. vCJD tissue distribution and transmission by transfusion--a worst-case scenario coming true?
    Aguzzi A; Glatzel M
    Lancet; 2004 Feb; 363(9407):411-2. PubMed ID: 14962516
    [No Abstract]   [Full Text] [Related]  

  • 15. Recipients of blood or blood products "at vCJD risk".
    Bird SM
    BMJ; 2004 Jan; 328(7432):118-9. PubMed ID: 14726314
    [No Abstract]   [Full Text] [Related]  

  • 16. Dental Instrument Sterilization and Creutzfeldt-Jakob Disease.
    Martin AP
    Aust Endod J; 2007 Dec; 33(3):143-4. PubMed ID: 18076584
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.
    Martin M; Trouvin JH
    Transfus Clin Biol; 2013 Sep; 20(4):398-404. PubMed ID: 23910008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A commentary on variant Creutzfeld-Jacob disease.
    Hoots K
    Haemophilia; 2010 Mar; 16(2):238-9. PubMed ID: 20487441
    [No Abstract]   [Full Text] [Related]  

  • 19. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease.
    Cervia JS; Sowemimo-Coker SO; Ortolano GA; Wilkins K; Schaffer J; Wortham ST
    Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
    van Aken WG
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1444-7. PubMed ID: 11503311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.